Colossal Biosciences closes funding round at ≥$20B valuation in 2026
Resolves: Colossal Biosciences announces a new funding round (equity or convertible) with a post-money valuation of at least $20 billion, confirmed in a press release or credible news report by December 31, 2026.
user-generated· fundraising
Colossal Biosciences closes funding round at ≥$20B valuation in 2026
Market overview
Given the report of ongoing talks and the company's recent revenue generation and spin-offs, it is likely Colossal will finalize a funding round at a valuation of at least $20 billion before the end of 2026.
fundraising prediction market
- Implied probability (Yes)
- 65%
- Closes
- 2026-12-31
About this prediction
Resolution criteria
Colossal Biosciences announces a new funding round (equity or convertible) with a post-money valuation of at least $20 billion, confirmed in a press release or credible news report by December 31, 2026.
Source: user-generated
More fundraising markets
- Newlight to secure Series A funding by Q2 2027 — 75% Yes
- Safeworld raises Series A by Q2 2027 — 70% Yes
- Maven Robotics to secure additional $50M funding by Q2 2027 — 75% Yes
- Fundamentum Fund III reaches $200M first close by 2027-01-31 — 85% Yes
- Cruise secures $500M+ new funding by mid-2027 — 60% Yes
- Inherent raises Series A of $100M+ by Feb 2027 — 55% Yes
- OpenAI closes $30B round by year-end 2026 — 75% Yes
- AOC's progressive PAC raises over $5 million by 2026 midterms — 75% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…